Research reveals that glutamine dependence is not unique to cancer, while methionine dependence is, indicating different therapeutic approaches.
GR is not a cancer-specific vulnerability, while MR is. Therefore, GR is not a promising cancer-therapy strategy.
No takes yet. Share an insight, caveat, or question.
MIYASHI et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: